ClinicalTrials.gg
Not yet recruitingNCT05558631LisaUpdated Sep 28, 2022

Longitudinal Study of Health Literacy in the Municipality of Leiria

An observational study in Health Literacy, sponsored by Instituto Politécnico de Leiria. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Instituto Politécnico de Leiria · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,003
Ages
18 Years and older
Sex
All
01

Study summary

Health literacy (HL) is a topic of increasing importance todays' ever-changing world. Over the past few decades, HL has gained importance, as it is a factor related to health behaviors and outcomes. In Portugal, the last survey was in 2016 and 61% of the population had a problematic or inadequate level of HL in general. Lisa is a cohort study that will measure HL in the adult population residing in the municipality of Leiria over the next 4 years, with measurements every 2 years. Over the years we will promote activities and interventions adjusted to the needs of Leiria's population. At the end we want to understand the changes during the years and improve the health care provided.

Read the detailed description

The main aim of this study is to measure HL in the adult population residing in the municipality of Leiria over the next 10 years. As secondary objectives, it is intended to characterize anxiety and depression, metabolic risk, alcoholism, and smoking in the in the same population sample and over the same period. The research design follows a longitudinal, prospective closed cohort study of Leiria's residents during ten years. Strengthening the report of observational studies in epidemiology (STROBE) guidelines were applied in alignment of the research objectives. The frequency of data assessment is set to two years, so participants will be contacted five times during the study. The sample will consist of residents of the municipality of Leiria aged 18 years or over, having been determined a sample size of 4003 (2001 men and 2002 women).

The team that conducted the 1st wave survey will be composed by 32 interviewers, who will be recruited by the Center for Innovative Care and Health Technology (ciTechCare) coordination board through a selection process composed of 2 stages: interview selection plus a theoretical and practical training session. The follow-ups of the cohort were decided to be conducted every two years by call. In the 1st wave a face-to-face interview will be conducted with the Computer Assisted Personal Interview (CAPI) system: all interviewers have a tablet with the software (LimeSurvey) which provided the questionnaire, designed by ciTechCare research team, applied to all subjects. Surveys will be administered online via the LimeSurvey platform at baseline and at 2 years, 4 years, 6 years, and 8 years post baseline (5 waves). The baseline and follow-up surveys will comprise the same battery of validated questionnaires and instruments designed to collect information on sociodemographic, lifestyle aspects (tobacco and physical activity), anthropometric variables, auto-report chronic diseases, metabolic risk, anxiety and depression and HL. It will take approximately 30 minutes to complete the survey.

Metabolic risk is assessed by the Finnish Diabetes Risk Score (FINDRISC), to evaluate symptoms of anxiety and depression we applied the Hospital Anxiety and Depression Scale (HADS) Portuguese validated version and HL will be measured by European Health Literacy Survey Questionnaire (HLS-EU-Q47).

Descriptive statistics (mean, standard deviation, median, minimum, maximum, interquartile range, absolute and relative frequencies) will be computed to describe the cohorts' sociodemographic characteristics. At baseline comparisons between groups (eg with and without anxiety) will be undertaken using t-tests for continuous normally distributed variables or Wilcoxon for continuous non-normally distributed variables. Chi-squared tests will be used for categorical variables, and Fisher's Exact test will be used for categorical variables within smaller sample sizes. Comparison between more than two groups will be performed through one-way analysis of variance (ANOVA) for continuous variables and chi-squared test for categorical variables. Factors significantly associated with any disease group will be included in a logistic regression model for further analysis. The effect of specific conditions on HL will be assessed by linear regression, univariable and then multivariable, controlling for potential confounders and also analyzing potential effect modification. Taking into consideration follow-up, the changes in HL, anxiety and depression will be each evaluated by means of variance analysis with measurement repetition. After checking the statistical model pre-requisites, sociodemographic characteristics will be added by means of linear regression analysis in the final model.

02

Conditions studied

  • Health Literacy

Browse trials for

03

In context

Literacy

203 studies on the registry are indexed under Literacy; 69 are open to participants now.

This study's planned enrollment of 4,003 is above the median of 256 across 28 observational studies indexed under Literacy.

Browse Literacy studies →

Lead sponsor

Instituto Politécnico de Leiria is the lead sponsor of 20 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population will be composed by adults (≥ 18 years old) who are non-institutionalized and living in private households in Leiria. Because there is no reliable list of households in Portugal, a random selection of points in the map of each location will be performed. Addresses will be selected, and afterwards the "random-walks" will start. Interviewers will register each selected address and, if someone is at home, they will collect information on age and gender of the different people living in that address and will give information about the study. In order to assure the successful data collection, up to three visits to each address (one during the weekend) will be made. At each address, the person whose birthday is closest to the day of the visit (aged 18 years or older) will be selected for the interview and, if available, will be immediately asked to answer the questionnaire.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study population will be composed by adults (≥ 18 years old) who are non-institutionalized and living in private households in Leiria.

Exclusion criteria

Exclusion Criteria:

  • Residing in hospitals, asylums, military barracks or prisons. Individuals who are unable to speak Portuguese or who reveal an inability to respond to the questionnaire, either directly or through a person who lives with them.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,003 participants (estimated)
Patient registry
No

Groups and cohorts

  • Residents of the municipality of Leiria aged 18 years or more.
06

What researchers measure

Primary outcomes

  1. Health literacy

    HL will be measured by European Health Literacy Survey Questionnaire (HLS-EU-Q16). HLS-EU-Q16 was developed to measure HL in populations, based on a conceptual framework. Each item in the questionnaire assesses the perceived difficulty of a specific health-related task for the respondent. The HLS-EU-Q16 was translated and validated for Portuguese population. The scale contains 16 items that measure HL. Each item assesses the perceived difficulty of completing a specific health-related task by asking "On a scale from very difficult to very easy, how easy would you say it is to \[e.g, find information on symptoms of illnesses that concern you\]?" Each item is rated on a 4-point Likert-type scale (1, very difficult; 2, fairly difficult; 3, fairly easy; 4, very easy). A higher difficulty score is assumed with lower HL.

    Time frame: Health literacy: measuring change over the next 10 years

Secondary outcomes

  1. Anxiety and depression

    To evaluate symptoms of anxiety and depression we applied the Hospital Anxiety and Depression Scale (HADS) Portuguese validated version. The HADS is a screening tool to apprehend clinically significant states of anxiety and depression in a non-psychiatric hospital setting. Individual anxiety and depression scores are calculated by summation of the appropriate seven items and thus can range from 0 to 21, with higher scores indicating higher levels of anxiety or depression, respectively. In both subscales, a score between 0 and 7 is "normal," between 8 and 10 "mild," between 11 and 14 "moderate," and between 15 and 21 "severe". Presence of anxiety and depression symptoms is defined when HADS scale is ≥11.

    Time frame: Anxiety and depression: measuring change over the next 10 years

  2. Metabolic risk

    Metabolic risk is assessed by the Finnish Diabetes Risk Score-FINDRISC (FINDRISC). FINDRISC is a simple and practical tool originally designed in Finland to identify individuals at high risk of type 2 diabetes mellitus onset, without the need for laboratory tests. The score is based on eight easily identifiable parameters (age, body mass index, waist circumference, hypertension, physical activity level, diet, occurrence of previous hyperglycemia, and family history of diabetes) and provides a measure of the probability of developing diabetes over the next 10 years. Findrisc score varies between 0 and 24. A risk score of 0-14 points indicates a low to moderate risk of diabetes (1-17% chance of diabetes over 10 years). A risk score of 15-20 points indicates a high risk of diabetes (33% chance of diabetes over 10 years). A risk score of \>20 points indicates a very high risk of diabetes (50% chance of diabetes over 10 years).

    Time frame: Metabolic risk: measuring change over the next 10 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2022; primary completion for Jan 2033, 122 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Sep 28, 2022
StartEst.
Nov 1, 2022
Primary completionEst.
Jan 31, 2033
CompletionEst.
Jan 31, 2033
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05558631
Lead sponsor
Instituto Politécnico de Leiria
Responsible party
Sara Dias (Principal investigator, Instituto Politécnico de Leiria) — Principal investigator
First posted
Sep 28, 2022
Start date
Nov 1, 2022 (estimated)
Primary completion
Jan 31, 2033 (estimated)
Completion
Jan 31, 2033 (estimated)
Last update
Sep 28, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion